Medication info

Ranicose 150 mg (Ranitidine Hydrochloride)

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Ranitidine Hydrochloride›168mg / 1 tablet
Manufacturer / importer
Cosmax Pharma Co., Ltd.
Appearance
White round film-coated tablet
Packaging
100 tablets (10 tablets/PTP*10), 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201905096 · Approved 2019.07.22

This product's status changed to Approval withdrawn on 2024.01.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of acid-related disorders (such as ulcers); improvement of gastric mucosal lesions; prevention of Mendelson syndrome
Who takes it
Adults · Children
Adult dose
Administer 150 mg of ranitidine per dose twice daily by mouth, in the morning and at bedtime. 1) Gastric and duodenal ulcers Administer 150 mg of this medicine per dose twice daily by mouth, or 300 mg once daily at bedtime. A higher healing rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg per dose twice daily, in the morning and at bedtime. The same dosage and administration apply when this medicine is used concomitantly to treat ulcers caused by nonsteroidal anti-inflammatory drugs or to prevent the development of gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. These conditions usually heal within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 150 mg of this medicine per dose twice daily for 8 weeks, or 300 mg once daily before bedtime. The dose may be increased to 150 mg per dose 4 times daily in patients with severe reflux esophagitis. 3) Zollinger-Ellison syndrome Initiate treatment with an initial dose of 150 mg of this medicine per dose 3 times daily, and increase the dose as needed. In severe cases, up to 6 g per day may be administered as directed by a physician. 4) In cases of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injection; once oral administration is possible, switch to oral administration and give 150 mg of this medicine per dose twice daily. 5) Preanesthetic medication (prevention of Mendelson's syndrome) Administer 150 mg of this medicine 2 hours before induction of anesthesia. In this case, it is preferable to also administer 150 mg on the night before surgery. 6) Improvement of gastric mucosal lesions (erosion, bleeding, redness, swelling) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis Administer 150 mg of this medicine per dose once daily at bedtime. 3. Patients with renal impairment For patients with severe renal impairment and a creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis decreases the blood concentration of the drug; therefore, adjust the dosing schedule immediately after hemodialysis. The dose may be adjusted appropriately according to age and symptoms.
Child dose
For patients aged 12 years and older, administer 75 mg of this medicine per dose twice daily by mouth (oral solution only). For patients aged 8 〜 18 years, up to 150 mg per dose (2 mg per kg of body weight) may be administered twice daily.

Ingredients

Manufacturer
Cosmax Pharma Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (such as ulcers); improvement of gastric mucosal lesions; prevention of Mendelson syndrome

  • Gastric and duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson’s syndrome
  • postoperative ulcers
  • gastric and duodenal ulcers caused by NSAID administration
  • gastric mucosal lesions
  • erosion
  • bleeding
  • redness
  • swelling
  • acute gastritis
View approved original text

This medication is effective for various gastrointestinal disorders such as gastric and duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. Additionally, it helps prevent Mendelson’s syndrome during surgery and anesthesia and aids in treating gastric ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). It can also improve symptoms such as gastric mucosal damage, bleeding, redness, and swelling that occur during acute exacerbation of acute and chronic gastritis. It is effective for various gastric mucosal lesions, including upper gastrointestinal bleeding and acute stress ulcers, and is used to relieve symptoms of heartburn and acid reflux due to excessive gastric acid secretion. It is widely used to treat and improve symptoms related to various gastrointestinal disorders.

How to take

Adult dose

Administer 150 mg of ranitidine per dose twice daily by mouth, in the morning and at bedtime. 1) Gastric and duodenal ulcers Administer 150 mg of this medicine per dose twice daily by mouth, or 300 mg once daily at bedtime. A higher healing rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg per dose twice daily, in the morning and at bedtime. The same dosage and administration apply when this medicine is used concomitantly to treat ulcers caused by nonsteroidal anti-inflammatory drugs or to prevent the development of gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. These conditions usually heal within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 150 mg of this medicine per dose twice daily for 8 weeks, or 300 mg once daily before bedtime. The dose may be increased to 150 mg per dose 4 times daily in patients with severe reflux esophagitis. 3) Zollinger-Ellison syndrome Initiate treatment with an initial dose of 150 mg of this medicine per dose 3 times daily, and increase the dose as needed. In severe cases, up to 6 g per day may be administered as directed by a physician. 4) In cases of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injection; once oral administration is possible, switch to oral administration and give 150 mg of this medicine per dose twice daily. 5) Preanesthetic medication (prevention of Mendelson's syndrome) Administer 150 mg of this medicine 2 hours before induction of anesthesia. In this case, it is preferable to also administer 150 mg on the night before surgery. 6) Improvement of gastric mucosal lesions (erosion, bleeding, redness, swelling) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis Administer 150 mg of this medicine per dose once daily at bedtime. 3. Patients with renal impairment For patients with severe renal impairment and a creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis decreases the blood concentration of the drug; therefore, adjust the dosing schedule immediately after hemodialysis. The dose may be adjusted appropriately according to age and symptoms.

Child dose

For patients aged 12 years and older, administer 75 mg of this medicine per dose twice daily by mouth (oral solution only). For patients aged 8 〜 18 years, up to 150 mg per dose (2 mg per kg of body weight) may be administered twice daily.

Precautions

This medication should not be used in patients who have previously shown allergic reactions to this medication’s components. It should also not be administered to patients with a rare disease called acute porphyria. For patients with impaired kidney function, the medication may remain in the body for a prolonged period, requiring dosage reduction or increased dosing intervals. Patients with decreased liver function should also use this medication cautiously. Caution is advised for patients with a history of drug allergies and for the elderly. Patients taking non-steroidal anti-inflammatory drugs, especially the elderly or those with a history of peptic ulcers, require regular examinations. This medication may mask symptoms of gastric cancer; thus, patients with gastric ulcers or those over middle age who have newly developed or changed indigestion must be assessed to confirm the absence of malignant diseases before treatment. Patients with Helicobacter pylori infections should undergo eradication therapy concurrently with treatment for gastric or duodenal ulcers. This medication may rarely cause severe allergic reactions such as anaphylactic shock; if any unusual symptoms occur, administration should be discontinued immediately and medical treatment sought. Symptoms of hypersensitivity, including hives, rash, difficulty breathing, and low blood pressure, may also occur. Rare blood abnormalities such as leukopenia and thrombocytopenia may manifest, necessitating checks if symptoms like systemic fatigue, bleeding, or fever arise. Symptoms of liver dysfunction may appear; if jaundice or abnormal liver function tests occur, use should be discontinued immediately. Gastrointestinal symptoms such as arrhythmia, constipation, nausea, and abdominal pain have been reported. Rare neurological symptoms such as dizziness, drowsiness, headaches, confusion, and insomnia may also occur. It is important to undergo regular blood tests, liver function tests, and kidney function tests. The elderly, patients with chronic lung disease, and diabetics may have an increased risk of pneumonia and should exercise caution. When experiencing dizziness or drowsiness while taking this medication, avoid driving or operating hazardous machinery. This medication may interact with other drugs, necessitating possible dosage adjustments or discontinuation of co-administered medications. Particularly when used with the anticoagulant warfarin, careful monitoring of blood coagulation times is essential. It is recommended to take this medication at least 2 hours apart from sucralfate. Women who are pregnant or may become pregnant, as well as breastfeeding women, should only use this medication when the benefits outweigh the risks. Safety in children has not been fully established, so it should be used cautiously. Older patients may have higher drug concentrations due to decreased kidney function; therefore, dosage and administration intervals need to be adjusted. This medication may cause false positive reactions in urine protein tests, thus it is advisable to use different testing methods. In case of overdose, appropriate treatment such as vomiting or gastric lavage is required; in severe cases, the medication may be removed via hemodialysis. It should be stored out of reach of children, and transferring to another container may pose a risk of accidents and degradation of quality.

Side effects

  • Anaphylactic shock
  • urticaria
  • angioedema
  • rash
  • fever
  • bronchospasm
  • hypotension
  • chest pain
  • granulocytopenia
  • elevated serum creatinine levels
Show 53 more
  • leukopenia
  • thrombocytopenia
  • bone marrow suppression
  • aplastic anemia
  • idiopathic aplastic anemia
  • dysplastic anemia
  • agranulocytosis
  • pancytopenia
  • acquired immune hemolytic anemia
  • eosinophilia
  • liver dysfunction
  • jaundice
  • hepatitis
  • bradycardia
  • atrioventricular block
  • tachycardia
  • vasculitis
  • constipation
  • nausea
  • vomiting
  • abdominal distention
  • abdominal pain
  • loss of appetite
  • diarrhea
  • acute pancreatitis
  • dizziness
  • drowsiness
  • seizures
  • headache
  • feeling of heaviness in the head
  • insomnia
  • agitation
  • anxiety
  • mental confusion
  • depression
  • hallucinations
  • blurred vision
  • involuntary movement disorders
  • consciousness disorders
  • hypertrophic muscle spasms
  • gynecomastia
  • excessive milk secretion
  • erectile dysfunction
  • decreased libido
  • arthralgia
  • myalgia
  • rhabdomyolysis
  • skin rash
  • erythema multiforme
  • alopecia
  • glossitis
  • skin itching
  • acute interstitial nephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air exposure and kept in a dry place at room temperature, between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

100 tablets (10 tablets/PTP*10), 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.